Faculty Collaboration Database

Switch from eculizumab to satralizumab in aquaporin 4 immunoglobulin G-seropositive neuromyelitis optica spectrum disorder: a case series report. Front Immunol 2024;15:1526563

Date

01/27/2025

Pubmed ID

39867894

Pubmed Central ID

PMC11757099

DOI

10.3389/fimmu.2024.1526563

Scopus ID

2-s2.0-85215693085 (requires institutional sign-in at Scopus site)   5 Citations

Abstract

OBJECTIVES: This case series describes adults with aquaporin 4 immunoglobulin G-seropositive (AQP4-IgG+) neuromyelitis optica spectrum disorder (NMOSD) who switched treatment from eculizumab to satralizumab.

METHODS: Case information for patients with AQP4-IgG+ NMOSD who received satralizumab for ≥6 months was obtained from US healthcare providers from April 2022 to January 2024. Patient characteristics, examination findings, diagnostic test results, treatment response, and adverse events were recorded.

RESULTS: Among the 5 patients (4 women and 1 man) included, ages ranged from 32 to 81 years and 4 patients self-identified as Black/African American and 1 as White. Time since confirmed NMOSD diagnosis ranged from 1 to 14 years. The reasons for initiating satralizumab were route of administration/patient preference (n=3) and inadequate disease control with eculizumab (n=2). The duration of satralizumab treatment was 10 to 31 months. All 5 patients were relapse-free with satralizumab, and adverse events they experienced were primarily asymptomatic laboratory abnormalities.

DISCUSSION: In this retrospective case series, satralizumab was effective and well tolerated in patients with NMOSD who switched from eculizumab due to route of administration/patient preference or inadequate disease control. These outcomes align with the long-term efficacy and safety outcomes with satralizumab in the phase 3 SAkura clinical trials.

Author List

Abboud H, Subei A, Sengul B, Shin RK, Goulette P, Walch R, Coté J, Pace R, Obeidat AZ, Ferayorni L, Gholizadeh S

Author

Ahmed Zayed Obeidat MD, PhD Associate Professor in the Neurology department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized
Aquaporin 4
Autoantibodies
Female
Humans
Immunoglobulin G
Male
Middle Aged
Neuromyelitis Optica
Treatment Outcome